In this episode, the panellists will evaluate past efforts, current trials, and the evolving landscape of HBV cure research. They will also weigh the patient-friendliness of these strategies, exploring potential pathways to a cure. How will the landscape of trials and research methodologies evolve in the future to facilitate this quest?
Faculty: Ahmed Elsharkawy (Moderator), Markus Cornberg (Faculty), Dickens Theodore (GSK Representative), Su Wang (Faculty)
This EASL Studio is supported by GSK.
Related episodes:
- EASL Studio from EASL Congress 2023: The bumpy road of Hepatitis B drug development successes and challenges
- EASL Studio S4E1: Hepatitis B elimination: how far behind are we and what do we need to change to achieve it?
- EASL Studio S3E9: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B —Who will be the winner, if at all?
- EASL Studio from ILC 2022: HBV/HDV Roundtable: HBV and HDV drug development – Where do we stand and where are we going?